"Dibenzothiepins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D003988
|
| MeSH Number(s) |
D02.886.680.350 D03.633.300.311
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dibenzothiepins".
Below are MeSH descriptors whose meaning is more specific than "Dibenzothiepins".
This graph shows the total number of publications written about "Dibenzothiepins" by people in this website by year, and whether "Dibenzothiepins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dibenzothiepins" by people in Profiles.
-
Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan. BMC Pediatr. 2023 01 21; 23(1):35.
-
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022 05; 22(5):718-730.
-
Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. Microbes Infect. 2022 Apr-May; 24(3):104895.
-
Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study. Pediatr Infect Dis J. 2020 08; 39(8):706-712.
-
Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 08; 39(8):700-705.